ABT ABBOTT LABORATORIES — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$99.67

Period return

-8.94 (-8.23%)

Volume

7.6M

2026-07-21O $100.52 H $101.83 L $99.34 C $99.67MA5 $98.02MA20 $94.28MA60 $90.14MA120 $98.57

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 16.High5 days ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — SOROS FUND MANAGEMENT LLC
신규 편입 · 포트폴리오 비중 0.08%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.56%
2026. 04. 27.LowBUY3 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 04. 20.LowBUY3 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 04. 18.LowBUY3 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 04. 17.LowBUY3 months ago
Oppenheimer: Outperform
US analyst rating / recommendation change.
2026. 04. 17.LowBUY3 months ago
RBC Capital: Outperform
US analyst rating / recommendation change.
2026. 04. 17.LowBUY3 months ago
Benchmark: Buy
US analyst rating / recommendation change.
2026. 04. 17.LowBUY3 months ago
Evercore ISI Group: Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $118.32 · 25 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 16.	After market close (AMC)	$1.28	—	—	$12.53B	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.76	—	—	$10.36B	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$2.38	—	—	$30.98B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$1.44	—	—	$20.34B	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	6,388,828	$655.94M	0.56%	—	New position
2	SOROS FUND MANAGEMENT LLC	SOROS FUND MANAGEMENT LLC	44,750	$4.59M	0.08%	—	New position

ABBOTT LABORATORIES애벗

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 04. 27.	BTIG	—	Maintain	Buy → Buy	—	BTIG: Buy
2026. 04. 20.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 04. 18.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2026. 04. 17.	Oppenheimer	—	Maintain	Outperform → Outperform	—	Oppenheimer: Outperform
2026. 04. 17.	RBC Capital	—	Maintain	Outperform → Outperform	—	RBC Capital: Outperform
2026. 04. 17.	Benchmark	—	Maintain	Buy → Buy	—	Benchmark: Buy